

June 18, 2020

Dear Shareholders

Christophe Weber  
President and Representative Director  
Takeda Pharmaceutical Company Limited  
1-1, Doshomachi 4-chome  
Chuo-ku, Osaka

Partial Correction to the Items Disclosed via the Internet Concerning the Notice of Convocation of the 144th Ordinary General Meeting of Shareholders

Takeda Pharmaceutical Company Limited (the “Company”) hereby reports that there is a part to be corrected in the Items Disclosed via the Internet Concerning the Notice of Convocation of the 144th Ordinary General Meeting of Shareholders and that the Company therefore decided to make the correction to the said part as described herein below.

1. Correction part:

5th line of item (iii) “Risk management rules and other systems” set forth on page 4 of the Items Disclosed via the Internet Concerning the Notice of Convocation of the 144th Ordinary General Meeting of Shareholders

2. Content of the correction:

[After correction]

..., and the systems through which the major potential risks and the mitigation plans thereof, etc. will be reported to the Risk, Ethics & Compliance Committee and the Board of Directors shall be established.

[Before correction]

..., and the systems through which the major potential risks and the mitigation plans thereof, etc. will be reported to the Audit, Risk and Compliance Committee and the Board of Directors shall be established.

[End of document]